Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is
known about brain metastases than cancer-related entities of similar incidence. Advances in …

Brain metastases (BMs) are an important source of morbidity and mortality in patients with
metastatic breast cancer (BC). As survival of patients with advanced BC considerably …

Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …

Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …

Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain
metastasis; however, its efficacy in preventing disease progression and the associated …

HER2-positive breast cancer represents 15%-20% of breast malignancies and is
characterized by an aggressive behavior and high recurrence rates. Anti-HER2-directed …

Purpose: Primary analysis of VISION showed tepotinib had durable clinical activity in
patients with MET exon 14 (MET ex14) skipping non–small cell lung cancer (NSCLC). We …

Purpose: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1,
and previously induced deep [objective response rate (ORR) 57.4%] and durable [median …